Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.72 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.72 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | CNR2 | P34972 | 7/20 | 0.60 |
| ▸ | CNR1 | P21554 | 6/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexadecanoic Acid Cyclopropylamide SCHEMBL1456457 | 0.98 | GNAI3 (0.75) | GNAI3GNAO1GNAI1MEN1ALDH1A1 | |
| SCHEMBL1234276 | 0.98 | GNAI3 (0.75) | GNAI3GNAO1GNAI1MEN1ALDH1A1 | |
| SCHEMBL28340804 | 0.98 | GNAI3 (0.75) | GNAI3GNAO1GNAI1MEN1ALDH1A1 | |
| SCHEMBL8361102 | 0.98 | GNAI3 (0.75) | GNAI3GNAO1GNAI1MEN1ALDH1A1 | |
| SCHEMBL11571826 | 0.98 | GNAI3 (0.75) | GNAI3GNAO1GNAI1MEN1ALDH1A1 | |
| SCHEMBL1457137 | 0.98 | GNAI3 (0.75) | GNAI3GNAO1GNAI1MEN1ALDH1A1 | |
| SCHEMBL3309908 | 0.94 | MEN1 (0.65) | GNAI3GNAO1GNAI1MEN1ALDH1A1 | |
| SCHEMBL9019501 | 0.93 | GNAI3 (0.64) | GNAI3GNAO1GNAI1MEN1ALDH1A1 | |
| SCHEMBL9019502 | 0.93 | GNAI3 (0.64) | GNAI3GNAO1GNAI1MEN1ALDH1A1 | |
| SCHEMBL17335659 | 0.92 | SMN1; SMN2 (0.74) | GNAI3GNAO1GNAI1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101186587-A | Method for synthesizing derivative of beta-amino acid and intermediate product thereof | KAILAIYING MEDICAL CHEMICAL TI (CN) | 2008-05-28 | — | — | CN | claimed |
| CN-110643833-B | Extraction system for separating magnesium from magnesium-containing brine by using secondary amide/tertiary amide composite solvent and extracting lithium, extraction method and application thereof | 湘潭大学 | 2021-04-20 | — | — | CN | disclosed |
| CN-110656249-B | Extraction system for separating magnesium from magnesium-containing brine by using secondary amide/alkane composite solvent, extraction method and application thereof | 湘潭大学 | 2021-03-23 | — | — | CN | disclosed |
| CN-110643833-A | Extraction system for separating magnesium from magnesium-containing brine by using secondary amide/tertiary amide composite solvent and extracting lithium, extraction method and application thereof | 湘潭大学 | 2020-01-03 | — | — | CN | disclosed |
| US-20160122386-A1 | V1A RECEPTOR AGONISTS | OCELOT BIO, INC. | 2016-05-05 | — | — | US | disclosed |
| CN-101454274-B | Processes and intermediates for preparing steric compounds | VERTEX PHARMA | 2014-05-07 | — | — | CN | disclosed |
| CN-102639499-A | Processes and intermediates | VERTEX PHARMA INC | 2012-08-15 | — | — | CN | disclosed |
| CN-101186587-B | Method for synthesizing derivative of beta-amino acid and intermediate product thereof | KAILAIYING MEDICAL CHEMICAL TIANJIN CO LTD | 2010-04-21 | — | — | CN | disclosed |
| US-7696250-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090170909-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| CN-101454274-A | Processes and intermediates for preparing steric compounds | VERTEX PHARMA (US) | 2009-06-10 | — | — | CN | disclosed |
| CN-101186587-A | Method for synthesizing derivative of beta-amino acid and intermediate product thereof | KAILAIYING MEDICAL CHEMICAL TI (CN) | 2008-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170909-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | GNAI3 4218/4885GNAO1 4626/4885GNAI1 3963/4885 |
| US-20160122386-A1 | V1A RECEPTOR AGONISTS | AVPR2, AVPR1A, AVPR1B | GNAI3 882/4885GNAO1 564/4885GNAI1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.